Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04875702 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Study acronym: TRUST
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 2 of 7 sitesv7
  2. Study sites: 6 to 7v6
  3. Start date: Jan 23, 2024 to Feb 22, 2024 Primary completion date: Nov 2028 to Sep 1, 2028 · Completion date: Nov 2028 to Oct 31, 2028 · Eligibility criteria shortened, about 103 words · 1 morev5 Show 4 more changesShow less
    • Primary completion date: Nov 2028 to Sep 1, 2028
    • Completion date: Nov 2028 to Oct 31, 2028
    • Eligibility criteria shortened, about 103 words
    • Site details revised at 1 of 6 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Phase: Not applicable to Phase 4 Trial status: Not Yet Recruiting to Recruiting · Primary and study completion dates: Nov 2026 to Nov 2028 · Start date changed from estimate of Nov 15, 2023 to Jan 23, 2024v4 Show 3 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Nov 2026 to Nov 2028
    • Start date changed from estimate of Nov 15, 2023 to Jan 23, 2024
  5. Start date: Sep 2023 to Nov 15, 2023 Primary and study completion dates: Sep 2026 to Nov 2026 · Interventions: Allopurinol (Drug), Antiinflammatory Agent for Gout Flare Prophylaxis (Drug) to Allopurinol (Drug), Colchicine 0.6 mg (Drug), Colchicine 1.2 mg (Drug), Naproxen 250 MG (Drug), Naproxen 500 Mg (Drug), Prednisone 40 mg… · Eligibility criteria expanded, about 237 words · 2 morev3 Show 5 more changesShow less
    • Primary and study completion dates: Sep 2026 to Nov 2026
    • Interventions: Allopurinol (Drug), Antiinflammatory Agent for Gout Flare Prophylaxis (Drug) to Allopurinol (Drug), Colchicine 0.6 mg (Drug), Colchicine 1.2 mg (Drug), Naproxen 250 MG (Drug), Naproxen 500 Mg (Drug), Prednisone 40 mg…
    • Eligibility criteria expanded, about 237 words
    • Study description expanded, about 307 words
    • Collaborators expanded, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  6. Start date: Jun 2022 to Sep 2023 Primary and study completion dates: Jun 2026 to Sep 2026 · Eligibility criteria expanded, about 8 words · Secondary endpoints: details revised at 1 of 1 entryv2 Show 3 more changesShow less
    • Primary and study completion dates: Jun 2026 to Sep 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 1 entry

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.
Trial Details
NCT Number NCT04875702
Lead Sponsor Massachusetts General Hospital
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions Gout
Enrollment 650 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov